We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+39.61%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$616M
AUM Growth
-$496M
Cap. Flow
-$674M
Cap. Flow %
-109.52%
Top 10 Hldgs %
58%
Holding
48
New
14
Increased
3
Reduced
16
Closed
15

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25.5M
2
PODD icon
Insulet
PODD
+$14.9M
3
TBPH icon
Theravance Biopharma
TBPH
+$14.8M
4
OCUL icon
Ocular Therapeutix
OCUL
+$12.7M
5
MRSN
Mersana Therapeutics
MRSN
+$10.8M

Top Sells

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$117M
2
SAGE
Sage Therapeutics
SAGE
+$111M
3
UTHR icon
United Therapeutics
UTHR
+$64.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$59.6M
5
CYTK icon
Cytokinetics
CYTK
+$55.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
26
Geron
GERN
$828M
$8.04M 1.31%
5,055,189
-4,630,339
-48% -$8.44M
KYNB
27
CALL
Kyntra Bio
KYNB
$27.2M
$6.18M 1%
+6,660
New +$7M
LUNG icon
28
Pulmonx
LUNG
$68.8M
$4.44M 0.72%
+64,345
New +$3.15M
IONS icon
29
Ionis Pharmaceuticals
IONS
$8.6B
$4.24M 0.69%
+75,000
New +$3.74M
SPRY icon
30
ARS Pharmaceuticals
SPRY
$509M
$3.24M 0.53%
+70,000
New +$2.34M
CALA
31
CALL
DELISTED
Calithera Biosciences, Inc
CALA
$2.46M 0.4%
+25,000
New +$2.19M
AUPH icon
32
Aurinia Pharmaceuticals
AUPH
$1.91B
$2.42M 0.39%
175,000
-2,310,327
-93% -$33.6M
TPST icon
33
Tempest Therapeutics
TPST
$13.7M
$578K 0.09%
1,385
-4,656
-77% -$1.61M
ABEO icon
34
Abeona Therapeutics
ABEO
$366M
– –
-155,717
Closed -$3.97M
ALLO icon
35
Allogene Therapeutics
ALLO
$649M
– –
-328,817
Closed -$12.4M
CYTK icon
36
Cytokinetics
CYTK
$10.5B
– –
-2,549,525
Closed -$55.2M
CYTK icon
37
PUT
Cytokinetics
CYTK
$10.5B
– –
-253,000
Closed -$5.48M
GKOS icon
38
Glaukos
GKOS
$9.83B
– –
-446,097
Closed -$22.1M
IVA
39
Inventiva
IVA
$1.06B
– –
-999,422
Closed -$11.8M
LNTH icon
40
Lantheus
LNTH
$6.49B
– –
-594,750
Closed -$7.54M
LQDA icon
41
Liquidia Corp
LQDA
$7.48B
– –
-1,189,607
Closed -$5.85M
SGMO
42
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-1,589,724
Closed -$15M
TGTX icon
43
TG Therapeutics
TGTX
$7.96B
– –
-1,600,000
Closed -$42.8M
VRAY
44
DELISTED
ViewRay, Inc.
VRAY
– –
-2,655,763
Closed -$9.29M
OYST
45
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
– –
-70,121
Closed -$1.48M
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-253,230
Closed -$13.9M
TBIO
47
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-943,339
Closed -$12.8M
BHVN
48
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-435,000
Closed -$28.3M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2020 Portfolio in Review

As of Q4 2020, Great Point Partners held 48 positions worth $616M, down 45% from $1.11B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $674M in Q4 2020, closing 15 positions and reducing 16 holdings. Its most notable exit was Cytokinetics, an estimated $55.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Rocket Pharmaceuticals worth $38.4M.

  • Great Point Partners's largest Q4 2020 buy was Rocket Pharmaceuticals: 700,000 shares worth $38.4M.
  • Great Point Partners added most to Intersect ENT, Inc in Q4 2020, an estimated $10.6M increase.
  • Great Point Partners's biggest Q4 2020 reduction was Iovance Biotherapeutics, cutting an estimated $117M.
  • Great Point Partners fully exited Cytokinetics in Q4 2020, selling an estimated $55.2M.
  • Great Point Partners's ten largest holdings make up 58% of its $616M portfolio in Q4 2020.
  • Great Point Partners opened 14 new positions and closed 15 in Q4 2020.
  • Great Point Partners's portfolio value fell 45% quarter-over-quarter to $616M.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.